Previous 10 | Next 10 |
2024-05-09 15:34:49 ET Annovis Bio ( NYSE: ANVS ) shares traded higher Thursday after the biotech said that initial data from a Phase 3 trial for its lead candidate buntanetap in early Parkinson’s disease is now expected in June.... Read the full article on Seeking Alph...
MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its ...
2024-05-02 16:00:35 ET Summary Annovis Bio's pipeline features a single therapeutic drug, Buntanetap, unlikely to showcase efficacy in AD or PD. Topline data of AD phase II/III trial was released in a press release, and featured a small post-hoc sub-population. The stock plumm...
2024-05-02 09:52:32 ET Summary Annovis Bio, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for neurodegenerative diseases like Alzheimer's and Parkinson's. Their pipeline includes Buntanetap/ANVS 402 for AD, PD, and Lewy Body Dementia, as well as ...
2024-05-02 00:19:50 ET Summary Annovis reported topline data from a Phase 2/3 trial in Alzheimer's disease, but the trial was a failure. The exclusion of 37% of the patient population and the focus on mild AD patients were not pre-specified, raising concerns. Annovis faces fin...
2024-04-30 13:43:00 ET More on mid-day movers & stocks. Bakkt Holdings, Inc. (BKKT) Q4 2023 Earnings Call Transcript Bakkt Holdings, Inc. 2023 Q4 - Results - Earnings Call Presentation Cemtrex, Inc. (CETX) Q1 2024 Earnings Call Transcript Bakkt announces ...
2024-04-30 10:01:07 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 19 out...
A look at the top 10 most actives in the United States Next.e.GO N.V. (EGOX) rose 38.0% to $0.0381 on volume of 59,468,925 shares Greenwave Technology Solutions Inc. (GWAV) rose 1.5% to $0.066 on volume of 45,683,331 shares Global Mofy Metaverse Limited (GMM) rose 68.4% to $1.5667 on volu...
2024-04-30 09:00:04 ET Sumant Kulkarni from Canaccord Genuity issued a price target of $26.00 for ANVS on 2024-04-30 07:34:00. The adjusted price target was set to $26.00. At the time of the announcement, ANVS was trading at $7.28. ANVS currently trades -67.60% versus it...
2024-04-30 08:24:49 ET More on pre-market losers & stocks. Biodexa shares rally 126% on rapamycin licensing deal NewGenIvf signs non-binding term sheet for potential reverse merger with European Wellness Investment Holdings Seeking Alpha’s Quant Rating on ...
News, Short Squeeze, Breakout and More Instantly...
Annovis Bio (NYSE: ANVS) , a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced receipt of approval from the U.S. Food an...
MALVERN, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...
2024-07-11 09:15:04 ET H.C. Wainwright analyst issues BUY recommendation for ANVS on July 11, 2024 07:54AM ET. The previous analyst recommendation was Buy. ANVS was trading at $12.08 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...